pancreatic cancer
Oncology · 2014–2019
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| paclitaxel, nanoparticle albumin-bound A 250 mg vial strength of nanoparticle albumin-bound paclitaxel for the treatment of metastatic adenocarcinoma of the pancreas (in combination with… | Mar 2019 | Recommended with restriction | none received |
| irinotecan (nanoliposomal) Treatment of metastatic pancreatic adenocarcinoma in adult patients with disease progression who have previously received gemcitabine-based therapy,… | Nov 2016 | Not recommended | 2 individuals Medical Oncology Group · Pancare Foundation · Rare Cancers Australia |
| paclitaxel-nanoparticle albumin bound First-line treatment of locally advanced, unresectable or metastatic adenocarcinoma of the pancreas, in combination with gemcitabine. | Mar 2014 | Recommended with restriction | unclear |
Who spoke
Medical Oncology Group · Pancare Foundation · Rare Cancers Australia
What the PBS pays
$16M in government benefit over 2024–25, across 113,120 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| paclitaxel, nanoparticle albumin-bound | $16.4M |
Appraised elsewhere
NICE, in England and Wales, has appraised 4 technologies for this condition, recommending 1 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| pegylated liposomal irinotecanPegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal) | TA1052 | terminated | 2025-04 |
| olaparibOlaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) | TA750 | terminated | 2021-12 |
| paclitaxelPaclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer | TA476 | recommended restricted | 2017-09 |
| pegylated liposomal irinotecanPegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine | TA440 | not recommended | 2017-04 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.